
41467_2025_58254_Fig1_HTML.png,

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with,

Ultrasound-Energized OX40L-Expressing Biohybrid for,

Age-Related Alterations in Peripheral Immune Landscape with,

89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in,

OX40/CD134 - Biocare Medical,

89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in,

Human TNF-alpha ELISA Kit - Quantikine DTA00D: R&D Systems,

12935_2021_2093_Fig1_HTML.png,

11307_2021_1621_Fig1_HTML.png,

Full article: Anticancer Potential of Bioactive Molecule,

Antitumor activity of MLN8054, an orally active small,

EAU 2023: 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear,

89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in,